Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia.
Leukemia and Lymphoma.
Times cited: 5
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): A randomised, controlled, phase 3 trial.
Times cited: 23
Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better?.
American Journal of Hematology.
Times cited: 8